Acelyrin, Inc. (SLRN)
| Market Cap | 316.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -264.41M |
| Shares Out | 100.33M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 902,556 |
| Open | 3.180 |
| Previous Close | 3.220 |
| Day's Range | 3.105 - 3.250 |
| 52-Week Range | 3.105 - 8.890 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.75 (+273.02%) |
| Earnings Date | Nov 13, 2024 |
About SLRN
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SLRN stock is "Buy." The 12-month stock price forecast is $11.75, which is an increase of 273.02% from the latest price.
News
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance
Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Execut...
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and a...
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
On Wednesday, Acelyrin Inc. SLRN confirmed that it was completing a 33% reduction in its workforce.
Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript
Acelyrin, Inc. (NASDAQ:SLRN) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - C...
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines i...
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by e...
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or ...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or ...
ACELYRIN INVESTOR DEADLINE APPROACHING
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options If you suffered losses exceedi...
FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "...
ACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wils...
SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or...